Autolus voluntarily elects U.S. domestic issuer reporting, no change to Q3 2023 financials

Autolus Therapeutics plc

Autolus will file periodic reports on Forms 10-K, 10-Q, and 8-K instead of foreign private issuer forms.
No financial or disclosure changes from the Form 6-K filed on November 2, 2023 for the quarter ended September 30, 2023.
Company retains foreign private issuer status, exempt from U.S. proxy rules, Regulation FD, and Section 16.
Effective immediately; first U.S. domestic issuer report to be filed later today (Q3 2023 Form 10-Q).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.